, Tracking Stock Market Picks
Enter Symbol:
Affymax, Inc. (AFFY) [hlAlert]

down 99.64 %

Affymax, Inc. (AFFY) rated Buy with price target $15 by Argus

Posted on: Monday,  Oct 4, 2010  8:25 AM ET by Argus

Argus rated Buy Affymax, Inc. (OTCBB: AFFY) on 10/04/2010. Previously Argus rated Buy Affymax, Inc. (OTCBB: AFFY) on 10/06/2009., when
the stock price was $23.98. Since then, Affymax, Inc. has lost 99.64% as of 08/27/2015's recent price of $0.09.
If you would have followed the previous Argus's recommendation on AFFY, you would have lost 99.64% of your investment in 2151 days.

Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a relatively small synthetic peptide-based erythropoiesis stimulating agent (ESA), which it is developing for the treatment of anemia patients with chronic renal failure. The Company is conducting Phase III clinical trials in patients suffering from chronic renal renal failure, on dialysis and not on dialysis (pre-dialysis). In August 2008, the Company and Takeda Pharmaceutical Company Limited (Takeda), agreed to suspend development of Hematide to treat chemotherapy induced anemia.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/4/2010 8:25 AM Buy
5.94 15.00
as of 12/31/2010
1 Week up  6.55 %
1 Month up  3.40 %
3 Months up  17.47 %
1 YTD down  -71.74 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/6/2009 8:25 AM Buy
23.98 30.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy